Cohort study examines hospitalization rates for RSV among infants receiving nirsevimab, indicating potential benefits.
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
No takes yet. Share an insight, caveat, or question.
Pelletier et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: